Biosimilar drugs step up complexity


The first ever generic monoclonal antibody therapies have been recommended for approval in Europe. The two biosimilar versions of infliximab (Johnson & Johnson’s Remicade) have passed assessment by the European Medicines Agency’s committee for medicinal products for human use, but will need to be fully approved by the European commission before they can be marketed.

Monoclonal antibodies are significantly larger and more complex than previously approved biosimilars, which include growth hormones and erythropoietin. Proving that they are functionally similar to the original drug is therefore complex. Both manufacturers, Celltrion and Hospira, had to complete human trials to prove that their generic infliximab products were as safe and effective as Remicade in treating autoimmune diseases.

Johnson & Johnson still has patent protection for Remicade in the majority of European countries. This means that the biosimilars, if finally approved, will either have to launch first in peripheral markets, or try to overturn the patent in court.


Related Content

Cast from the same mould?

31 May 2011 Premium contentFeature

news image

Development of generic biological drugs is gathering momentum. But as Rajendrani Mukhopadhyay finds out, the welcome they are...

US poised to approve its first ‘biosimilar’ drug

9 January 2015 Business

news image

FDA panel recommends Sandoz’s copy of Amgen’s Neupogen

Most Commented

Electric choc treatment promises lower fat chocolate

22 June 2016 Research

news image

Problem of reduced fat chocolate gumming up factories’ pipelines overcome

Behind closed doors: How to win the Nobel prize

7 October 2015 Comments

news image

Bengt Norden addresses the myths and rumours surrounding the world's most prestigious science prize